131-iodine tositumomab for non-Hodgkin's lymphoma - horizon scanning review

Record ID 32002000529
Authors' objectives:

To summarise the available evidence on 131-Iodine tositumomab for non-Hodgkin's lymphoma (NHL).

Authors' recommendations: - Clinical impact: Iodine-131 tositumomab is entering a market with many other treatment options. Trial results suggest a beneficial effect on response and median time to relapse, although full results from trials are still awaited. An estimated 300 to 550 patients may be eligible for therapy with iodine-131 tositumomab. - Service impact: There is unlikely to be a significant service impact associated with the introduction of iodine-131 tositumomab, however an inpatient stay is required because of the possibility of radiation exposure to other people. The radiolabelling process and regulations will be familiar to nuclear medicine departments. - Additional factors: Because of its prolonged nature any drug with the potential to lengthen survival in NHL will be welcomed by doctors, patients and carers. - Financial and overall NHS impact: During the course of NHL patients are given many different regimes and iodine-131 tositumomab will be an additional cost, but in some cases it may replace or postpone other treatment options. This needs to be clarified in cost-effectiveness data.
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
URL for published report: http://www.hsric.nihr.ac.uk/search
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Lymphoma, Non-Hodgkin
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.